JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

Polyclonal Immunoglobulin Free Light Chain Levels Predict Survival in Myeloid Neoplasms

(2012) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management

(2011) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients

(2011) A. Tefferi et al.   BLOOD

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm

(2011) K. Shide et al.   BLOOD

EZH2 mutational status predicts poor survival in myelofibrosis

(2011) P. Guglielmelli et al.   BLOOD

How I treat myelofibrosis

(2011) A. Tefferi   BLOOD

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells

(2011) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

(2011) Gregor Hoermann et al.   FASEB JOURNAL

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

(2011) T. Hornakova et al.   HAEMATOLOGICA

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

(2011) Jean-Jacques Kiladjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia

(2011) Ryan C Russell et al.   NATURE MEDICINE

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

(2011) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

(2011) Y Nakaya et al.   Blood Cancer Journal

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients

(2010) Alejandra Martínez-Trillos et al.   ANNALS OF HEMATOLOGY

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

(2010) S. T. Oh et al.   BLOOD

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells

(2010) X. Wang et al.   BLOOD

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Lnk constrains myeloproliferative diseases in mice

(2010) Alexey Bersenev et al.   JOURNAL OF CLINICAL INVESTIGATION

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase-2 trial of low-dose pomalidomide in myelofibrosis

(2010) K H Begna et al.   LEUKEMIA

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

(2009) Y. Wang et al.   BLOOD

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

(2009) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors

(2008) Ifat Geron et al.   CANCER CELL

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

(2008) T L Lasho et al.   LEUKEMIA

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD